Brehm Michael, Zeus Tobias, Strauer Bodo Eckehard
Internal Clinic B, Department of Cardiology, University of Duesseldorf, Germany.
Herz. 2002 Nov;27(7):611-20. doi: 10.1007/s00059-002-2435-y.
Augmentation of myocardial performance in experimental models of therapeutic infarction and heart failure has been achieved by transplantation of exogenous cells into damaged myocardium. The quest for suitable donor cells has prompted research into the use of both embryonic stem cells and adult somatic stem cells.
Recently, there has been a growing body of evidence that multipotent somatic stem cells in adult bone marrow exhibit tremendous functional plasticity and can reprogram in a new environmental tissue niche to give rise to cell lineages specific for new organ site. This phenomenon has made huge impact on myocardial biology, while multipotent adult bone marrow hematopoeitic stem cells and mesechymal stem cells can repopulate infarcted rodent myocardium and differentiate into both cardiomyocytes and new blood vessels.
These data, coupled with the identification of a putative primitive cardiac stem cell population in the adult human heart, may open the way for novel therapeutic modalities for enhancing myocardial performance and treating heart failure.
在治疗性梗死和心力衰竭的实验模型中,通过将外源性细胞移植到受损心肌中来增强心肌功能。对合适供体细胞的探索促使人们对胚胎干细胞和成人成体干细胞的应用进行研究。
最近,越来越多的证据表明,成人骨髓中的多能成体干细胞表现出巨大的功能可塑性,并且可以在新的环境组织微环境中重新编程,以产生特定于新器官部位的细胞谱系。这一现象对心肌生物学产生了巨大影响,而成人骨髓造血干细胞和间充质干细胞可以重新填充梗死的啮齿动物心肌,并分化为心肌细胞和新血管。
这些数据,再加上在成人心脏中鉴定出假定的原始心脏干细胞群体,可能为增强心肌功能和治疗心力衰竭的新型治疗方法开辟道路。